InnoCore Pharmaceuticals’ Post

"There are some issues related to the healthcare industry, we are talking about common issues like harmonization of specifications, problem of nitrosamines, etc. I think a common approach to the problem will be more helpful". 💬 R.K. Agrawal, National President, Bulk Drug Manufacturers Association in India (BDMAI) He emphasizes the importance of collaborative solutions in tackling the diverse risks confronting the pharmaceutical industry. Gain valuable insights from our 4th regional chapter meeting discussion. 🎥Watch the complete conversation below, and don't forget to re-post to spread this insight." 🔄 #pharmaceuticals #collaboration

For any of my colleagues out there planning for a Rare Disease launch, take a listen to our webinar today at 11 am with Pharmaceutical Executive. It will bring together the cross-functional perspectives of Medical, Commercial, and Market Access!

For a pharmaceutical company, launching a drug represents the culmination of extensive research and development efforts. Across the typical stages of drug launch - planning the launch, the launch itself, and the post-launch drug lifecycle management, #CommercialAnalytics can guide pharmaceutical companies to leverage the power of real-time analytics for informed decision-making and enhanced patient outcomes. 🎯 From Action to Impact: To drive tangible results, we orchestrated a series of targeted initiatives with specific outcomes. Our latest #blog by experts Puneet Kaur Dhingra Mahima Dhingra, and Amritha Sharma has use cases, solutions, and more…  Read here 👉 <https://lnkd.in/d9hU6gna #druglaunch #Pharma #HealthTech

Did you miss AscellaHealth Europe's strategic guide with insights on how to bring specialty and rare disease products to market successfully? Download the guide here: https://lnkd.in/eh9tVPri Our step-by-step guide covers how to develop an effective master plan for all of the elements that drive commercial success of your product. #raredisease #drugdevelopment #clinicaltrials #marketaccess #pharmaceutical #AscellaHealth

Save your time and gain free, clear insights, data, and much more about the #APImarket with us! 😎 If you are a professional in the #pharmaceutical industry, you cannot miss it! In this analysis made by us, you'll dive deep into the trends shaping the pharmaceutical API landscape. Stay tuned for key insights that could impact your strategic decision! 📅 #HPAPI #CDMO

Everyone knows Anaheim for the great Anaheim Ducks. But did you know that this year, Anaheim is also the city of pharmaceuticals? The Drug Delivery Summit 2024 is here, and we'll be there. Karin Cooke, PhD, Director of Business Development North America at Conscio Pharma division, part of the Conscio Group network, will be at the Summit. You can arrange a meeting with her to discuss how our global group approaches the formulation of new dosage forms and the specialties we are able to deliver to our customers around the world. Examples include our innovative drug delivery systems in the form of transdermal patches and orally dissolving films. https://lnkd.in/eXEThfze Karin is also a registered standby speaker, so keep an eye on her profile for more information about her presentation on this topic: Innovative and customized formulation approaches in immediate and modified release drug products. #consciogroup #pharmaceuticalresearch #consciopharmaceuticals #analyticalsolutions #drugdeliverysummit2024 #transdermalpatches

Do you want to know how we can help with your formulation development projects? Meet us on DDS in Anaheim. Let us know, and we will provide you with proof that we understand what we are talking about when it comes to drug formulation, CMC, clinical development, bioanalytics, manufacturing, and much more. This is our Conscio Group - Quality Science for a Healthy Future

One week left before our PharmaExec webinar: Navigating Success During a Rare Disease Product Launch. https://lnkd.in/eNXGaMS3 Hear lessons learned from Medical, Market Access, and Commercial experts.

One year ago, when at a strategic level we decided to carry out this rebranding, we were clear that the new identity had to reflect the values of AMSbiopharma: - 𝙒𝙊𝙍𝙆: The work done these years, from management, laboratory organization, sales, marketing... all the work done summarized in one image, was not simple... - 𝙀𝙑𝙊𝙇𝙐𝙏𝙄𝙊𝙉: AMSbiopharma has evolved over the years, serving our clients, the market, adapting quickly, growing to reach where we were not, where they needed us. - 𝙃𝙊𝙋𝙀: That which all of us who form/are part of AMSBiopharma convey daily in our work and which we wish to spread to all those who get to know us. Today we present a change that represents the new stage of AMSbiopharma, an exciting stage of growth, work and enthusiasm, that takes us to the proposed goals. One step on a long road, a step that confirms that the best is yet to come. Seguimos!!

This paper presents recommendations from a #WorkingGroup on drug innovativeness, pricing, and reimbursement. It reviews drug pricing models, evaluation processes, and negotiation strategies. Key recommendations include defining criteria for comparators and endpoints, using drug value as a primary driver for pricing, maintaining flexibility in negotiations, reintroducing #ManagedEntryAgreements, and fostering early dialogue between the #ItalianMedicineAgency and pharmaceutical companies, with structured involvement of scientific societies and patient representatives. | https://ow.ly/KnoU50SBc8v